{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:10:27Z","timestamp":1763809827731},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40618-018-0864-6","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T07:42:12Z","timestamp":1521186132000},"page":"1283-1288","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation"],"prefix":"10.1007","volume":"41","author":[{"given":"A.","family":"Campenn\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Siracusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63:11\u201330","journal-title":"CA Cancer J Clin"},{"key":"864_CR2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1002\/cncr.24416","volume":"115","author":"AY Chen","year":"2009","unstructured":"Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988\u20132005. Cancer 115:3801\u20133807","journal-title":"Cancer"},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA 295:2164\u20132167","journal-title":"JAMA"},{"key":"864_CR4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.021","author":"A Campenn\u00ec","year":"2014","unstructured":"Campenn\u00ec A, Giovanella L, Siracusa M, Stipo ME, Alibrandi A, Cucinotta M, Ruggeri RM, Baldari S (2014) Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? Thyroid. https:\/\/doi.org\/10.1089\/thy.2014.021","journal-title":"Thyroid"},{"issue":"4","key":"864_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","volume":"140","author":"L Davis","year":"2014","unstructured":"Davis L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317\u2013322. https:\/\/doi.org\/10.1001\/jamaoto.2014.1","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"864_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoto.2016.0230","volume":"142","author":"LG Morris","year":"2016","unstructured":"Morris LG, Tuttle RM, Davies L (2016) Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg 142(7):709\u2013711. https:\/\/doi.org\/10.1001\/jamaoto.2016.0230","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"864_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3892\/ol.2015.3416","volume":"10","author":"S Lei","year":"2015","unstructured":"Lei S, Ding Z, Ge J, Zhao D (2015) Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: a retrospective 10-year follow-up study. Oncol Lett Sep 10(3):1749\u20131754","journal-title":"Oncol Lett Sep"},{"key":"864_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000367","author":"A Campenn\u00ec","year":"2015","unstructured":"Campenn\u00ec A, Giovanella L, Pignata SA, Violi MA, Siracusa M, Alibrandi A, Moleti M, Amato E, Ruggeri RM, Vermiglio F, Baldari S (2015) Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario. Nucl Med Commun. https:\/\/doi.org\/10.1097\/MNM.0000000000000367","journal-title":"Nucl Med Commun"},{"issue":"1","key":"864_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/cco.0000000000000148","volume":"27","author":"R Vigneri","year":"2015","unstructured":"Vigneri R, Malandrino P, Vigneri P (2015) The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 27(1):1\u20137. https:\/\/doi.org\/10.1097\/cco.0000000000000148 (Review)","journal-title":"Curr Opin Oncol"},{"key":"864_CR10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0527","author":"SY Sohn","year":"2016","unstructured":"Sohn SY, Park WY, Shin HT, Bae JS, Ki CS, Oh YL, Kim SW, Chung JH (2016) Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid cancer. Thyroid. https:\/\/doi.org\/10.1089\/thy.2015.0527","journal-title":"Thyroid"},{"key":"864_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<34::AID-SSU7>3.0.CO;2-2","volume":"16","author":"BR Haugen","year":"1999","unstructured":"Haugen BR (1999) Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34\u201341","journal-title":"Semin Surg Oncol"},{"issue":"2","key":"864_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12(2):245\u2013262","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"864_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40618-016-0491-z","volume":"39","author":"J Yu","year":"2016","unstructured":"Yu J, Mai W, Cui Y, Kong L (2016) Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis. J Endocrinol Invest 39(11):1285\u20131293","journal-title":"J Endocrinol Invest"},{"key":"864_CR14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7811","author":"L Jin","year":"2016","unstructured":"Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O (2016) BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.7811","journal-title":"Oncotarget"},{"issue":"5","key":"864_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3275\/6722","volume":"33","author":"V Sykorova","year":"2010","unstructured":"Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B (2010) BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 33(5):318\u2013324. https:\/\/doi.org\/10.3275\/6722","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"864_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40618-016-0526-5","volume":"40","author":"R Ciampi","year":"2017","unstructured":"Ciampi R, Romei C, Pieruzzi L, Tacito A, Molinaro E, Agate L, Bottici V, Casella F, Ugolini C, Materazzi G, Basolo F, Elisei R (2017) Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. J Endocrinol Invest 40(1):55\u201362. https:\/\/doi.org\/10.1007\/s40618-016-0526-5","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"864_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40618-015-0420-6","volume":"39","author":"JO Paulsson","year":"2016","unstructured":"Paulsson JO, Svahn F, Welander J, Brunaud L, S\u00f6derkvist P, Gimm O, Stenman A, Juhlin CC (2016) Absence of the BRAF V600E mutation in pheochromocytoma. J Endocrinol Invest 39(6):715\u2013716. https:\/\/doi.org\/10.1007\/s40618-015-0420-6","journal-title":"J Endocrinol Invest"},{"key":"864_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1775","author":"R Elisei","year":"2012","unstructured":"Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2012-1775","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"864_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"Riesco-Eizaguirre G, Guti\u00e9rrez-Mart\u00ednez P, Garc\u00eda-Cabezas MA, Nistal M, Santisteban P (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na\u2009+\/I\u2212 targeting to the membrane. Endocr Relat Cancer 13(1):257\u2013269","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"864_CR20","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90(12):6373\u20136379","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"864_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40618-015-0410-8","volume":"39","author":"D Xu","year":"2016","unstructured":"Xu D, Yin Y, Hou L, Dai WJ (2016) Surgical management of secondary hyperparathyroidism: how to effectively reduce recurrence at the time of primary surgery. Endocrinol Invest 39(5):509\u2013514. https:\/\/doi.org\/10.1007\/s40618-015-0410-8","journal-title":"Endocrinol Invest"},{"key":"864_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e3283342319","author":"A Campenn\u00ec","year":"2010","unstructured":"Campenn\u00ec A, Violi MA, Ruggeri RM, Sindoni A, Moleti M, Vermiglio F, Baldari S (2010) Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. Nucl Med Commun. https:\/\/doi.org\/10.1097\/MNM.0b013e3283342319","journal-title":"Nucl Med Commun"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1210\/jc.2003-030305","volume":"88","author":"H Namba","year":"2003","unstructured":"Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical Implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393\u20134397","journal-title":"J Clin Endocrinol Metab"},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1210\/jc.2003-030838","volume":"88","author":"MN Nikiforova","year":"2003","unstructured":"Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399\u20135404","journal-title":"J Clin Endocrinol Metab"},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3349\/ymj.2004.45.5.818","volume":"45","author":"KH Kim","year":"2004","unstructured":"Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818\u2013821","journal-title":"Yonsei Med J"},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1210\/jc.2003-031425","volume":"89","author":"E Puxeddu","year":"2004","unstructured":"Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G et al (2004) BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414\u20132420","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"864_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40618-014-0166-6","volume":"37","author":"P Agretti","year":"2014","unstructured":"Agretti P, Niccolai F, Rago T, De Marco G, Molinaro A, Scutari M, Di Cosmo C, Di Coscio G, Vitale M, Maccheroni M, Vitti P, Tonacchera M (2014) BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. J Endocrinol Invest 37(10):1009\u20131014. https:\/\/doi.org\/10.1007\/s40618-014-0166-6","journal-title":"J Endocrinol Invest"},{"key":"864_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3285-1","author":"L Giovanella","year":"2016","unstructured":"Giovanella L, Campenni\u2019 A, Treglia G, Verburg FA, Trimboli P, Ceriani L, Bongiovanni M (2016) Molecular imaging with 99mTc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-015-3285-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"864_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF03027374","volume":"20","author":"OK Nuriye","year":"2006","unstructured":"Nuriye OK, Hulya AK, Gulseren A (2006) Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative 1-131 scanning results. Ann Nucl Med 20(6):393\u2013397","journal-title":"Ann Nucl Med"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/thy.1997.7.327","volume":"7","author":"F Grunwald","year":"1997","unstructured":"Grunwald F, Menzel C, Bender H et al (1997) Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7:327\u2013335","journal-title":"Thyroid"},{"key":"864_CR31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-59259-199-2_24","volume-title":"Thyroid cancer. A comprehensive guide to clinical management","author":"L Wartoksky","year":"2000","unstructured":"Wartoksky L (2000) An approach to the management of patients with scan negative, thyroglobulin positive, differentiated thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, pp 251\u2013261"},{"key":"864_CR32","first-page":"227","volume":"101","author":"Z Puch","year":"1999","unstructured":"Puch Z, Handkiewicz-Junak D, Zajisz A, Orlef A, Roskosz J, Jarzab B (1999) The usefulness of MIBI scintigraphy for post-operative monitoring of patients with thyroid cancer. Pol Arch Med Wewn 101:227\u2013232","journal-title":"Pol Arch Med Wewn"},{"key":"864_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s002590050527","volume":"27","author":"D Rubello","year":"2000","unstructured":"Rubello D, Mazzarotto R, Casara D (2000) The role of technetium 99-m methoxy- isobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 27:431\u2013440","journal-title":"Eur J Nucl Med"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1089\/thy.1998.8.1091","volume":"8","author":"MS Alam","year":"1998","unstructured":"Alam MS, Kasagi K, Misaki T, Miyamoto S, Iwata M, Iida Y et al (1998) Diagnostic value of technetium-99m methoxyisobutylisonitrile (99m-Tc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid 8:1091\u20131100","journal-title":"Thyroid"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-0038-1629852","volume":"37","author":"M Dietlein","year":"1998","unstructured":"Dietlein M, Scheidhaaauer K, Voth E, Theissen P, Schicha H (1998) Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 37:12\u201317","journal-title":"Nuklearmedizin"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0038-1629865","volume":"36","author":"H Elser","year":"1997","unstructured":"Elser H, Henze M, Hermann C, Eckert W, Mende U (1997) 99mTc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmedizin 36:7\u201312","journal-title":"Nuklearmedizin"},{"key":"864_CR37","first-page":"352","volume":"38","author":"S Miyamoto","year":"1997","unstructured":"Miyamoto S, Kasagi T, Alam MS, Konishi J (1997) Evaluation of technetium-99m\u2014MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 38:352\u2013356","journal-title":"J Nucl Med"},{"issue":"1","key":"864_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Scherman SI, Sosa JA et al (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer\u2014The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1\u2013133","journal-title":"Thyroid"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0864-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T10:25:51Z","timestamp":1603967151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0864-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0864-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]},"assertion":[{"value":"8 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}